Shed Best Alternatives for Each Use Case

What Shed Actually Offers

Shed operates as a direct-to-consumer telehealth platform that pairs patients with prescribers who can order compounded GLP-1 receptor agonists. The service runs on a subscription model: patients pay a flat monthly fee that bundles the provider consultation, medication, and shipping.

The Compounding Model

Compounded medications are mixed by 503A or 503B pharmacies rather than manufactured by Novo Nordisk or Eli Lilly. The FDA has explicitly stated that compounded versions of semaglutide and tirzepatide are not FDA-approved and carry distinct safety risks, including potential differences in sterility, potency, and purity compared to brand-name formulations.

Who Shed Works For

The platform appeals to patients who cannot afford brand-name GLP-1s (which list above $1,000/month without insurance) and who want a low-friction sign-up process. Shed's onboarding is asynchronous: patients complete a questionnaire, a provider reviews it, and a prescription ships if approved.

Where Shed Falls Short

Shed does not accept insurance. It does not offer non-GLP-1 weight management medications like metformin, naltrexone-bupropion (Contrave), or phentermine-topiramate (Qsymia). And it provides limited longitudinal clinical support compared to programs that include dietitians, metabolic lab panels, or structured behavioral coaching. For patients whose obesity is intertwined with type 2 diabetes, cardiovascular risk, or PCOS, a GLP-1-only platform may miss the bigger clinical picture.

Why Consider Alternatives

The weight-loss telehealth market has expanded rapidly since semaglutide's FDA approval for chronic weight management in June 2021. A 2024 KFF survey found that roughly 6% of U.S. Adults reported having used a GLP-1 receptor agonist for weight loss or diabetes. That demand created dozens of telehealth platforms with different strengths.

Cost Pressure

Compounded semaglutide pricing varies widely across platforms. Some charge $150 to $300 per month; others have driven prices below $100. If cost is the primary barrier, shopping across platforms can save $50 to $150 monthly.

Clinical Complexity

Patients with a BMI above 40, multiple comorbidities, or a history of bariatric surgery need more than a prescription. The 2024 American Association of Clinical Endocrinology (AACE) obesity guidelines recommend comprehensive, team-based obesity care that includes nutritional counseling, behavioral modification, and ongoing metabolic monitoring. A platform that only ships injections may leave gaps.

Medication Access

The FDA's enforcement discretion around GLP-1 compounding has shifted multiple times. If compounded semaglutide or tirzepatide becomes unavailable due to regulatory changes, patients locked into a compounding-only platform lose access. Platforms that also prescribe brand-name medications or non-GLP-1 alternatives offer a safety net.

Best Alternative for Cost: Ro Body Program

Ro (formerly Roman) launched its Body Program with compounded semaglutide at prices that undercut most competitors. As of early 2026, Ro advertises compounded semaglutide starting around $99 per month, bundled with provider visits and metabolic support.

What Ro Does Differently

Ro pairs the GLP-1 prescription with a structured program that includes body composition tracking, provider messaging, and goal-setting tools. The platform also prescribes brand-name Wegovy and Zepbound for patients with insurance coverage, giving it flexibility that Shed lacks.

Limitations

Ro's clinical depth still trails programs like Calibrate. The provider interactions are primarily asynchronous, and Ro does not routinely order comprehensive metabolic panels (CMP, HbA1c, lipids) unless the prescriber flags a need. Patients with diabetes or cardiovascular disease should confirm that Ro's protocol includes appropriate lab monitoring.

In the STEP-1 trial (N=1,961), participants receiving brand-name semaglutide 2.4 mg weekly achieved 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo [1]. Compounded versions have not been studied in comparable randomized controlled trials, so extrapolating these results to any compounded formulation requires caution.

Best Alternative for Clinical Depth: Calibrate

Calibrate markets itself as a "metabolic health company" rather than a weight-loss subscription. Its one-year program includes a licensed clinician, a dedicated coach, metabolic lab work, and a structured curriculum covering nutrition, exercise, sleep, and emotional health.

The Calibrate Protocol

Calibrate prescribes brand-name GLP-1s (Wegovy, Zepbound, Mounjaro) and works with patients' insurance to obtain prior authorization. The program requires baseline labs (fasting glucose, HbA1c, lipid panel, liver enzymes) and repeats them at defined intervals. This aligns with AACE's recommendation that obesity pharmacotherapy be embedded in a comprehensive treatment plan rather than prescribed in isolation [2].

Who Should Choose Calibrate Over Shed

Patients with type 2 diabetes, prediabetes (HbA1c 5.7%, 6.4%), metabolic syndrome, or a BMI ≥ 35 with comorbidities benefit most from Calibrate's structured approach. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease [3]. Capturing that cardiovascular benefit requires appropriate patient selection and monitoring, not just a prescription.

Drawbacks

Calibrate costs more than Shed or Ro. The program fee (separate from medication cost) has historically ranged from $1,500 to $1,900 per year. Patients without insurance coverage for brand-name GLP-1s face an additional $1,000+ monthly medication expense. Calibrate does not offer compounded alternatives.

Best Alternative for Medication Variety: Henry Meds

Henry Meds stands out for the breadth of its formulary. Beyond compounded semaglutide and tirzepatide, the platform prescribes oral semaglutide (Rybelsus), liraglutide, and adjunctive medications like metformin and topiramate.

Why Variety Matters

Not every patient tolerates injectable GLP-1s. Gastrointestinal side effects (nausea, vomiting, diarrhea) affected 44% of semaglutide-treated participants in the STEP-1 trial [1]. For patients who cannot tolerate injections or prefer oral dosing, having a provider who can pivot to Rybelsus (oral semaglutide, 14 mg daily) or a non-GLP-1 combination matters. The OASIS-1 trial (N=667) showed that oral semaglutide 50 mg produced 15.1% weight loss at 68 weeks versus 2.4% for placebo [4], though the 50 mg dose is not yet commercially available in the U.S.

Henry Meds Pricing

Henry Meds charges a consultation fee plus medication cost. Compounded semaglutide pricing tends to fall in the $200 to $350 per month range, higher than Ro but bundled with more frequent provider check-ins. The platform also ships combination formulations (e.g., semaglutide + B12) that some patients prefer.

Limitations

Henry Meds does not accept insurance for brand-name GLP-1s. Its strength is compounding flexibility and formulary breadth, not insurance navigation.

Best Alternative for Insurance Coverage: Found

Found (formerly Found Health) is one of the few telehealth weight-loss platforms that accepts commercial insurance for brand-name GLP-1 prescriptions. For patients whose plans cover Wegovy or Zepbound, Found can reduce out-of-pocket costs to a copay rather than full cash price.

How Found Handles Prior Authorization

Found's clinical team submits prior authorization requests directly to insurers. This is a meaningful service: a 2023 AMA survey found that 94% of physicians reported care delays associated with prior authorization, and GLP-1s are among the most commonly restricted drug classes. Found's PA workflow can compress the timeline from weeks to days for straightforward cases.

Found's Clinical Model

Beyond GLP-1s, Found prescribes metformin, bupropion-naltrexone, and topiramate. The platform includes health coaching and nutritional guidance, though its depth falls between Shed's minimal model and Calibrate's intensive program.

When Found Is Not the Right Fit

Found's insurance pathway works only if the patient's plan covers weight-management medications. Many employer-sponsored plans and Medicare Part D exclude anti-obesity medications entirely. The Treat and Reduce Obesity Act has been introduced in Congress multiple times but has not yet passed as of 2026. For patients without coverage, Found's cash-pay pricing offers no meaningful advantage over Shed.

Head-to-Head Comparison Table

| Feature | Shed | Ro Body | Calibrate | Henry Meds | Found | |---|---|---|---|---|---| | Compounded GLP-1 | Yes | Yes | No | Yes | No | | Brand-name GLP-1 | No | Yes | Yes | Limited | Yes | | Insurance accepted | No | Partial | Yes | No | Yes | | Non-GLP-1 Rx options | No | Limited | Yes | Yes | Yes | | Baseline lab work | No | No | Yes | No | Varies | | Behavioral coaching | Minimal | Moderate | Intensive | Minimal | Moderate | | Approx. Monthly cost (cash) | $150, $300 | $99, $199 | $125, $160 + Rx | $200, $350 | $99, $199 + Rx |

Safety Considerations for All Compounded GLP-1 Platforms

Any platform selling compounded semaglutide or tirzepatide operates in a regulatory gray zone. The FDA issued an updated safety alert in 2024 warning consumers about adverse events linked to compounded GLP-1 products, including reports of dosing errors and contamination [5].

What to Verify Before Choosing Any Compounded Platform

Confirm the compounding pharmacy holds a valid state license and, ideally, 503B outsourcing facility registration with the FDA. Ask whether the pharmacy conducts third-party potency and sterility testing on each batch. Request a Certificate of Analysis (COA). If the platform cannot provide this documentation, treat that as a red flag.

Ongoing Monitoring

Regardless of platform, patients on GLP-1 therapy should have periodic monitoring. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends monitoring for pancreatitis symptoms, gallbladder disease, and thyroid nodules in patients on GLP-1 receptor agonists [6]. Platforms that do not support lab work or symptom screening leave that responsibility entirely to the patient and their primary care provider.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "Anti-obesity medications work best when they are part of a comprehensive treatment plan that includes dietary counseling, physical activity, and regular follow-up. A prescription alone is not a treatment plan" [7].

The American Gastroenterological Association's 2024 clinical practice guideline further noted: "Pharmacotherapy for obesity should be prescribed within a framework that includes lifestyle intervention and regular reassessment of efficacy and tolerability" [8].

How to Choose the Right Platform for You

Matching a platform to your situation requires honest assessment of three variables: your budget, your medical complexity, and your insurance coverage.

Budget-First Patients

If you are otherwise healthy, have a BMI between 27 and 35 with at least one weight-related comorbidity, and your primary barrier is cost, Ro's Body Program or a similarly priced compounding platform gives you the lowest monthly spend. Confirm that the pharmacy is 503B-registered and request batch COAs.

Medically Complex Patients

If you have type 2 diabetes, cardiovascular disease, NAFLD/MASH, or a BMI above 40, choose a platform that orders labs, monitors metabolic markers, and can escalate care. Calibrate or a brick-and-mortar obesity medicine practice with telehealth capability fits best. The SURMOUNT-1 trial (N=2,539) showed that tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks [9]. Capturing maximal benefit from these agents requires dose titration guided by lab data and symptom tracking.

Insurance-Eligible Patients

If your plan covers Wegovy or Zepbound, use a platform that handles prior authorization. Found or Calibrate can manage this process. Paying cash for a compounded version of a drug your insurance would cover at a $30 copay is not a good use of money.

Is Shed Legit?

Shed is a licensed telehealth platform that connects patients with prescribers and fulfills prescriptions through compounding pharmacies. It is not a scam. But "legit" and "optimal" are different standards. Shed's model is narrow: one medication class, no insurance, minimal clinical scaffolding. For patients who simply want access to compounded GLP-1s at a mid-range price with minimal friction, Shed delivers that. For patients who need more, the alternatives above fill the gaps.